CL2023001709A1 - Métodos para detección de anticuerpos antifármaco contra anticuerpos de factor xi y/o factor xia - Google Patents
Métodos para detección de anticuerpos antifármaco contra anticuerpos de factor xi y/o factor xiaInfo
- Publication number
- CL2023001709A1 CL2023001709A1 CL2023001709A CL2023001709A CL2023001709A1 CL 2023001709 A1 CL2023001709 A1 CL 2023001709A1 CL 2023001709 A CL2023001709 A CL 2023001709A CL 2023001709 A CL2023001709 A CL 2023001709A CL 2023001709 A1 CL2023001709 A1 CL 2023001709A1
- Authority
- CL
- Chile
- Prior art keywords
- factor
- antibodies
- methods
- detection
- antidrug
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
- G01N33/686—Anti-idiotype
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/36—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54306—Solid-phase reaction mechanisms
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54393—Improving reaction conditions or stability, e.g. by coating or irradiation of surface, by reduction of non-specific binding, by promotion of specific binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
- G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
- G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
- G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
- G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
- G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
- G01N2333/96433—Serine endopeptidases (3.4.21)
- G01N2333/96441—Serine endopeptidases (3.4.21) with definite EC number
- G01N2333/96452—Factor XI (3.4.21.27)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Diabetes (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063127536P | 2020-12-18 | 2020-12-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2023001709A1 true CL2023001709A1 (es) | 2023-11-17 |
Family
ID=82059801
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2023001709A CL2023001709A1 (es) | 2020-12-18 | 2023-06-13 | Métodos para detección de anticuerpos antifármaco contra anticuerpos de factor xi y/o factor xia |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US20240077497A1 (https=) |
| EP (1) | EP4264278A4 (https=) |
| JP (1) | JP2023554347A (https=) |
| KR (1) | KR20230121120A (https=) |
| CN (1) | CN116601491A (https=) |
| AR (1) | AR124434A1 (https=) |
| AU (1) | AU2021401421A1 (https=) |
| CA (1) | CA3199482A1 (https=) |
| CL (1) | CL2023001709A1 (https=) |
| CO (1) | CO2023008150A2 (https=) |
| CR (1) | CR20230313A (https=) |
| CU (1) | CU20230031A7 (https=) |
| EC (1) | ECSP23053645A (https=) |
| IL (1) | IL302904A (https=) |
| JO (1) | JOP20230137A1 (https=) |
| MX (1) | MX2023007281A (https=) |
| PE (1) | PE20231679A1 (https=) |
| TW (1) | TW202242414A (https=) |
| WO (1) | WO2022133263A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2025523802A (ja) * | 2022-07-13 | 2025-07-25 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 分析物を検出するための弱酸性免疫アッセイ |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UY36751A (es) * | 2015-06-26 | 2017-01-31 | Novartis Ag | Anticuerpos de factor xi y métodos de uso |
| EP3713965A1 (en) * | 2017-11-22 | 2020-09-30 | Novartis AG | Reversal binding agents for anti-factor xi/xia antibodies and uses thereof |
| MX2020004921A (es) * | 2017-11-29 | 2020-08-27 | Hoffmann La Roche | Ensayo de anticuerpo antifarmaco con supresion de interferencia del objetivo. |
| WO2020231992A1 (en) * | 2019-05-13 | 2020-11-19 | Regeneron Pharmaceuticals, Inc. | Improved competitive ligand binding assays |
-
2021
- 2021-12-17 CA CA3199482A patent/CA3199482A1/en active Pending
- 2021-12-17 PE PE2023001878A patent/PE20231679A1/es unknown
- 2021-12-17 IL IL302904A patent/IL302904A/en unknown
- 2021-12-17 WO PCT/US2021/064117 patent/WO2022133263A1/en not_active Ceased
- 2021-12-17 EP EP21907922.5A patent/EP4264278A4/en active Pending
- 2021-12-17 AU AU2021401421A patent/AU2021401421A1/en active Pending
- 2021-12-17 CU CU2023000031A patent/CU20230031A7/es unknown
- 2021-12-17 JP JP2023536045A patent/JP2023554347A/ja active Pending
- 2021-12-17 MX MX2023007281A patent/MX2023007281A/es unknown
- 2021-12-17 KR KR1020237023913A patent/KR20230121120A/ko active Pending
- 2021-12-17 CR CR20230313A patent/CR20230313A/es unknown
- 2021-12-17 CN CN202180084721.3A patent/CN116601491A/zh active Pending
- 2021-12-20 TW TW110147788A patent/TW202242414A/zh unknown
- 2021-12-20 AR ARP210103581A patent/AR124434A1/es unknown
-
2023
- 2023-06-13 CL CL2023001709A patent/CL2023001709A1/es unknown
- 2023-06-14 JO JOJO/P/2023/0137A patent/JOP20230137A1/ar unknown
- 2023-06-15 US US18/335,507 patent/US20240077497A1/en active Pending
- 2023-06-22 CO CONC2023/0008150A patent/CO2023008150A2/es unknown
- 2023-07-17 EC ECSENADI202353645A patent/ECSP23053645A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JOP20230137A1 (ar) | 2023-06-14 |
| ECSP23053645A (es) | 2023-08-31 |
| CU20230031A7 (es) | 2024-02-07 |
| WO2022133263A1 (en) | 2022-06-23 |
| TW202242414A (zh) | 2022-11-01 |
| CR20230313A (es) | 2023-08-18 |
| AU2021401421A1 (en) | 2023-06-22 |
| US20240077497A1 (en) | 2024-03-07 |
| IL302904A (en) | 2023-07-01 |
| EP4264278A4 (en) | 2024-11-27 |
| AR124434A1 (es) | 2023-03-29 |
| AU2021401421A9 (en) | 2024-10-24 |
| EP4264278A1 (en) | 2023-10-25 |
| CA3199482A1 (en) | 2022-06-23 |
| JP2023554347A (ja) | 2023-12-27 |
| KR20230121120A (ko) | 2023-08-17 |
| CN116601491A (zh) | 2023-08-15 |
| MX2023007281A (es) | 2023-09-04 |
| CO2023008150A2 (es) | 2023-06-30 |
| PE20231679A1 (es) | 2023-10-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020009278A (es) | Ensayos para detectar la neurodegeneración. | |
| MX2020001575A (es) | Materiales y métodos para evaluar y tratar el cáncer. | |
| EA201890869A2 (ru) | Применение ингибиторов тирозинкиназы брутона (btk) | |
| BR112017009151A2 (pt) | ensaios para detectar subgrupos imunológicos de célula t e métodos de uso dos mesmos | |
| CL2019002438A1 (es) | Uso de biomarcadores en la identificación de pacientes con cáncer que serán sensibles al tratamiento con un inhibidor de prmt5. | |
| BR112016029190A2 (pt) | método e sistema de detecção de defeitos em tubulações. | |
| CR20210373A (es) | Tratamiento agudo y tratamiento rápido de la cefalea usando anticuerpos anti-cgrp | |
| MX2019011657A (es) | Combinacion de un anticuerpo anti ligando 1 de muerte programada (pd-l1) e inhibidor de proteina cinasa dependiente de acido desoxirribonucleico (dna-pk) para tratamiento de cancer. | |
| MX2007004079A (es) | Detecci??n de niveles elevados de prote??na her-2/neu en celulas cancerosas circulantes y tratamiento. | |
| MX2021008268A (es) | Tratamiento de cefalea por uso excesivo de medicamentos usando anticuerpos anti-cgrp o anti-cgrp-r. | |
| BR112016007037A2 (pt) | método para detectar câncer pancreático, anticorpo monoclonal e kit | |
| MX2021014963A (es) | Metodos para predecir el beneficio terapeutico de la terapia con anti-cd19 en pacientes. | |
| PE20141450A1 (es) | Ensayo de lisiloxidasa-homologo 2 y metodos de uso del mismo | |
| MX2020006660A (es) | Biomarcadores de tolerancia inmunitaria inducida por metotrexato. | |
| CL2023001709A1 (es) | Métodos para detección de anticuerpos antifármaco contra anticuerpos de factor xi y/o factor xia | |
| EA201992431A1 (ru) | Комбинированная иммунотерапия рака с использованием пента-аза-макроциклического кольцевого комплекса | |
| MX2020009363A (es) | Un método para detectar magea4. | |
| MX2023009414A (es) | Metodos para detectar una cadena ligera de neurofilamento en plasma y fluido cefalorraquideo. | |
| MX2024008320A (es) | Biomarcadores transcripcionales para la respuesta a activadores inmunitarios innatos | |
| CL2023000476A1 (es) | Anticuerpos monoclonales, composiciones y métodos para detectar el factor d de complemento | |
| MX2019010478A (es) | Sistemas y métodos para la detección y cuantificación enzimáticas de a1c. | |
| BR112016021424A2 (pt) | Transferência de dados automática | |
| MX2021009281A (es) | Metodos de deteccion de legionella. | |
| BR112023019433A2 (pt) | Tratamentos de combinação para melanoma | |
| BR112018076005A2 (pt) | anticorpo monoclonal isolado, método para medir o nível de gama-glutamil-l-epsilon-lisina (ggel), método ex vivo para o monitoramento de apoptose, uso de um anticorpo monoclonal específico para gama-glutamil-l-epsilon-lisina (ggel), métodos para monitorar a eficácia de um tratamento indutor de apoptose, método de tratamento de uma doença associada a apoptose desregulada, kit para o monitoramento de apoptose, método de tratamento de sepse e dispositivo de imunoensaio de fluxo lateral |